Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Verdeso
Overview
What is Verdeso?
VERDESO Foam is a white to off-white petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid.
Chemically, desonide is (11,16)-11,21-dihydroxy-16,17-[(1-methylethylidene)-bis(oxy)]-pregna-1,4-diene-3,20-dione. The structural formula of desonide is represented below:
Desonide has a molecular formula of CHO and a molecular weight of 416.51. Desonide is a white powder or crystal that is practically insoluble in water, sparingly soluble in ethanol and in acetone, and soluble in chloroform. Each gram of VERDESO Foam contains 0.5 mg desonide. The foam also contains anhydrous citric acid, cetyl alcohol, cyclomethicone, isopropyl myristate, light mineral oil, white petrolatum, polyoxyl 20 cetostearyl ether, potassium citrate (monohydrate), propylene glycol, purified water, sorbitan monolaurate, and phenoxyethanol as a preservative.
VERDESO Foam is dispensed from an aluminum can pressurized with a hydrocarbon (propane/butane) propellant.
What does Verdeso look like?
What are the available doses of Verdeso?
Foam, 0.05%. Each gram of VERDESO Foam contains 0.5 mg of desonide in a white to off-white petrolatum-based emulsion aerosol foam.
What should I talk to my health care provider before I take Verdeso?
How should I use Verdeso?
VERDESO (desonide) Foam, 0.05% is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
Patients should be instructed to use VERDESO Foam for the minimum amount of time necessary to achieve the desired results because of the potential for VERDESO Foam to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Treatment should not exceed 4 consecutive weeks.
VERDESO Foam is not for oral, ophthalmic, or intravaginal use.
A thin layer of VERDESO Foam should be applied to the affected area(s) twice daily. Shake the can before use. VERDESO Foam should be dispensed by inverting the can (upright actuation will cause loss of the propellant which may affect product delivery). Dispense the smallest amount of foam necessary to adequately cover the affected area(s) with a thin layer.
The medication should not be dispensed directly on the face. Dispense in hands and gently massage into affected areas of the face until the medication disappears. For areas other than the face, the medication may be dispensed directly onto the affected area. Take care to avoid contact with the eyes or other mucous membranes.
Patients should dispense the smallest amount of foam necessary to adequately cover the affected area with a thin layer. Therapy should be discontinued when control is achieved. If no improvement is seen within 4 weeks, reassessment of diagnosis may be necessary. The safety and efficacy of VERDESO Foam has not been established beyond 4 weeks of use. Treatment should not exceed 4 consecutive weeks.
Unless directed by a physician, VERDESO Foam should not be used with occlusive dressings.
What interacts with Verdeso?
Sorry No Records found
What are the warnings of Verdeso?
Sorry No Records found
What are the precautions of Verdeso?
Sorry No Records found
What are the side effects of Verdeso?
Sorry No records found
What should I look out for while using Verdeso?
None.
What might happen if I take too much Verdeso?
Topically applied VERDESO Foam can be absorbed in sufficient amounts to produce systemic effects.
Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids.
How should I store and handle Verdeso?
Store at USP controlled room temperature 68°F to 77°F (20°C to 25°C) with excursions permitted between 15°C (59°F) and 30°C (86°F). Contents under pressure. Do not puncture or incinerate. Avoid contact with eyes or other mucous membranes. Keep out of reach of children. Morphine Sulfate Suppositories are available in cartons of 12. Easy-to-open, color-coded:5 mg Suppositories (Red)12's NDC 0574-7110-1210 mg Suppositories (Light Blue)12's NDC 0574-7112-1220 mg Suppositories (Light Green)12's NDC 0574-7114-1230 mg Suppositories (Purple)12's NDC 0574-7116-12Morphine Sulfate Suppositories are available in cartons of 12. Easy-to-open, color-coded:5 mg Suppositories (Red)12's NDC 0574-7110-1210 mg Suppositories (Light Blue)12's NDC 0574-7112-1220 mg Suppositories (Light Green)12's NDC 0574-7114-1230 mg Suppositories (Purple)12's NDC 0574-7116-12Morphine Sulfate Suppositories are available in cartons of 12. Easy-to-open, color-coded:5 mg Suppositories (Red)12's NDC 0574-7110-1210 mg Suppositories (Light Blue)12's NDC 0574-7112-1220 mg Suppositories (Light Green)12's NDC 0574-7114-1230 mg Suppositories (Purple)12's NDC 0574-7116-12Morphine Sulfate Suppositories are available in cartons of 12. Easy-to-open, color-coded:5 mg Suppositories (Red)12's NDC 0574-7110-1210 mg Suppositories (Light Blue)12's NDC 0574-7112-1220 mg Suppositories (Light Green)12's NDC 0574-7114-1230 mg Suppositories (Purple)12's NDC 0574-7116-12Morphine Sulfate Suppositories are available in cartons of 12. Easy-to-open, color-coded:5 mg Suppositories (Red)12's NDC 0574-7110-1210 mg Suppositories (Light Blue)12's NDC 0574-7112-1220 mg Suppositories (Light Green)12's NDC 0574-7114-1230 mg Suppositories (Purple)12's NDC 0574-7116-12
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in the treatment of atopic dermatitis is unknown.
The contribution to efficacy by individual components of the vehicle has not been established.
Non-Clinical Toxicology
None.Generally, effects of morphine may be potentiated by alkalizing agents and antagonized by acidifying agents. Analgesic effect of morphine is potentiated by chlorpromazine and methocarbamol, CNS depressants such as anesthetics, hypnotics, barbiturates, phenothiazines, chloral hydrate, glutethimide, sedatives, MAO inhibitors (including procarbazine hydrochloride), antihistamines, beta-blockers (propranolol), alcohol, furazolidone and other narcotics may enhance the depressant effects of morphine.
Morphine may increase anticoagulant activity of Coumadin and other anticoagulants.
VERDESO Foam has been shown to reversibly suppress the HPA axis.
Topical application of VERDESO Foam may result in systemic absorption and effects including HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, facial swelling, glycosuria, withdrawal, and growth retardation in children. Use of VERDESO Foam for longer than 4 weeks may suppress the immune system
Conditions that augment systemic absorption include the application of topical corticosteroids over large body surface areas, prolonged use, or the addition of occlusive dressings. Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression.
An adrenocorticotropic hormone (ACTH) stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.
The effect of VERDESO Foam on HPA axis function was investigated in pediatric subjects in one trial. In this trial, subjects with atopic dermatitis covering at least 25% of their body applied VERDESO Foam twice daily for 4 weeks. Three out of 75 subjects (4%) displayed adrenal suppression after 4 weeks of use based on the cosyntropin stimulation test. The laboratory suppression was transient; all subjects had returned to normal when tested 4 weeks post-treatment.
Pediatric patients may be more susceptible than adults to systemic toxicity from equivalent doses of VERDESO Foam due to their larger skin surface-to-body mass ratios.
Concomitant therapy with topical corticosteroids should be used with caution because a cumulative effect may occur.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
515Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).